Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing

American Journal of Gastroenterology

Volumn 107, Issue 11, 2012, Pages 1684-1692

  Bessissow, Talat ^a   Lemmens, Bart ^b   Ferrante, Marc ^a   Bisschops, Raf ^a   Van Steen, Kristel ^c   Geboes, Karel ^b   Van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a   De Hertogh, Gert ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PLASMACYTOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SEROLOGY; ULCER HEALING; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; INTESTINAL MUCOSA; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84869487488     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.301     Document Type: Article

References (26)

1. Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study) . Inflamm Bowel Dis 2006; 12: 543-50. (Pubitemid 43977734)
2. D' Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
3. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453-5. (Pubitemid 46580492)
4. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 338-46.
5. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
6. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
7. Lichtenstein GR, Yan S, Bala M et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulising Crohn's disease. Gastroenterology 2005; 128: 862-9. (Pubitemid 40523539)
8. Fr ø slie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22. (Pubitemid 47187355)
9. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
10. Bitton A, Peppercorn MA, Antonioli DA et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20. (Pubitemid 32061864)
11. Moum B, Ekbom A, Vatn MH et al. Clinical course during the 1st year aft er diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997; 32: 1005-12. (Pubitemid 27433664)
12. Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011; 60: 3-9.
13. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956; 1: 1315-8.
14. Riley SA, Mani V, Goodman MJ et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
15. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9. (Pubitemid 38182302)
16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9. (Pubitemid 18010466)
17. Geboes K, Riddell R, Ost A et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47: 404-9.
18. Brown SR, Hartly JE, Hill J et al. Contemporary Coloproctology. Springer-Verlag London Limited: London, UK, 2012, pp 227.
19. Riley SA, Mani V, Goodman MJ et al. Why do patients with ulcerative colitis relapse? Gut 1990; 31: 179-83. (Pubitemid 20092152)
20. Saverymuttu SH, Hodgson HJ, Chadwick VS et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27: 809-13. (Pubitemid 16058500)
21. Schoepfer AM, Beglinger C, Straumann A et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-8.
22. Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 870-9.
23. Nostrant TT, Kumar NB, Appelman HD. Histopathology differentiates acute self-limited colitis from ulcerative colitis. Gastroenterology 1987; 92: 318-28. (Pubitemid 17231710)
24. Scott BB, Goodall A, Stephenson P et al. Rectal mucosal plasma cell in inflammatory bowel disease. Gut 1983; 24: 519-24. (Pubitemid 13106281)
25. Keren DF, Appelman HD, Dobbins WO et al. Correlation of histopathologic evidence of disease activity with the presence of the immunoglobulincontaining cells in the colons of patients with inflammatory bowel disease. Hum Pathol 1984; 15: 753-7.
26. Brandtzaeg P, Baklein K, Fausa O et al. Immunohistochemical characterization of local immunoglobulin formation in ulcerative colitis. Gastroenterology 1974; 66: 1123-36.